EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients

C D Villarreal-Villarreal, E Boland-Rodriguez, D Mares-Custodio, D Asz-Sigall, J F Molina-de la Garza, D Saceda-Corralo, S Vano-Galvan

Actas Dermo-Sifiliográficas · 2026

DOI: 10.1016/j.ad.2025.104569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Actas Dermo-Sifiliográficas, 2026. Verfasst von C D Villarreal-Villarreal und 6 weiteren Autor:innen. Beteiligte Einrichtung: CEDAVI Derma Experts, Hair Restoration Unit, Monterrey, Mexico; Tecnológico de Monterrey - Escuela de Medicina y Ciencias de la Salud, Monterrey, Mex…. Hauptthemen laut MEDLINE: Minoxidil, COVID-19, Alopecia. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although it is self-limiting, hair loss can be very distressing, and some patients may seek medical treatment to help promote hair regrowth. Low-dose oral minoxidil (LDOM) has emerged as a novel and very efficient therapy for different types of alopecia. However, information on its safety and efficacy profile in the management of CATE remains scarce. This study aims to evaluate the treatment response to LDOM in CATE patients. METHODS: We conducted a retrospective study at a single dermatology center. Adult patients diagnosed with telogen effluvium from December 2020 to October 2022, with a prior history of SARS-CoV-2 infection, and treated with LDOM were included. The efficacy of LDOM was evaluated with the hair-shedding score (HSS). RESULTS: In all, 69 patients, 50 (72.5%) women and 19 (27.5%) men were included. A total of 55 patients (79.7%) exhibited mild and moderate symptoms; 8 (11.5%), severe disease; and 6 (8.7%) remained asymptomatic. The time elapsed between COVID-19 and telogen effluvium diagnosis was 117 days (80-181). The HSS continuously decreased during the 2nd, 3rd, and 4th visits after treatment initiation. Compared with baseline, the median (interquartile range) HSS was significantly lower at the 2nd visit (5 [5-6]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MinoxidilCOVID-19AlopeciaHumansRetrospective StudiesFemaleMaleMiddle AgedAdultAdministration, OralAgedTreatment OutcomeSARS-CoV-2

Stichwörter der Autor:innen

Androgenetic alopeciaCOVID-19Hair lossHair sheddingMinoxidilTelogen effluvium

Substanzen

Minoxidil

Autor:innen und Institutionen

  • CEDAVI Derma Experts, Hair Restoration Unit, Monterrey, Mexico; Tecnológico de Monterrey - Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico. Electronic address: dr.cesarvillarrealderma@gmail.com.
  • CEDAVI Derma Experts, Hair Restoration Unit, Monterrey, Mexico.
  • Tecnológico de Monterrey - Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico.
  • Trichology Clinic, Dermatology Department, Hospital General Manuel Gea Gonzalez, Mexico.
  • Servicio de Dermatología, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; Trichology Unit, Grupo de Dermatologia Pedro Jaén, Madrid, Spain; Departamento de Biología de Sistemas, Facultad de Medicina, Univer…
  • Servicio de Dermatología, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; Trichology Unit, Grupo de Dermatologia Pedro Jaén, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Universidad de Alc…

Zitieren

APA

Villarreal-Villarreal, C. D., Boland-Rodriguez, E., Mares-Custodio, D., Asz-Sigall, D., Molina-de la Garza, J. F., Saceda-Corralo, D., & Vano-Galvan, S. (2026). Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2025.104569

Vancouver

Villarreal-Villarreal CD, Boland-Rodriguez E, Mares-Custodio D, Asz-Sigall D, Molina-de la Garza JF, Saceda-Corralo D, et al. Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients. Actas Dermo-Sifiliográficas. 2026. doi:10.1016/j.ad.2025.104569

BibTeX
@article{VillarrealVillarreal2026,
  author = {Villarreal-Villarreal, C D and Boland-Rodriguez, E and Mares-Custodio, D and Asz-Sigall, D and Molina-de la Garza, J F and Saceda-Corralo, D and Vano-Galvan, S},
  title = {Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2026},
  doi = {10.1016/j.ad.2025.104569}
}
Kostenlos starten →